Since its inception over 75 years ago, the Division of Vascular Surgery and Endovascular Therapy at Emory has had an international role in advancing the treatment of arterial and venous disease. In the early 1990s, vascular surgery in general and our division in particular began shifting focus from traditional, open procedures to minimally-invasive and endovascular therapy techniques, pharmaceuticals, and gene therapy. This transition was validated by a wide range of clinical trials undertaken by our board-certified faculty physicians, who became recognized as national leaders in training, research, and the performance of endovascular procedures.

Our division's clinical research program provides patients with the opportunity to benefit from cutting-edge technology through more than 24 FDA approved clinical trials. Past and current research areas include the genetics of abdominal aortic aneurysm and peripheral artery disease, novel stents for treating thoracic and abdominal aortic aneurysms, artificial venous valves and numerous other projects. The basic science research program has received over $16.7 million of funding from the NIH, NSF, and JDRF over the past 11 years. Projects are ongoing in the areas of reparative medicine, organ fabrication, and the design of engineered living systems.

A two-year ACGME-approved program, the Emory Residency in Vascular Surgery and Endovascular Therapy was one of the first programs in the U.S. established to provide advanced postgraduate training for the care of the patient with vascular disease. The program emphasizes surgical and endovascular therapy for venous and arterial disease, vascular medicine, and vascular diagnostics.